← 返回

识别用于预测胰腺腺癌预后和免疫活性的自噬相关基因特征

英文原题:Identification of an autophagy-related gene signature for predicting prognosis and immune activity in pancreatic adenocarcinoma.

查看英文原题

Identification of an autophagy-related gene signature for predicting prognosis and immune activity in pancreatic adenocarcinoma.

PubMed 2022/04/29(内容时间) Sci Rep Q1 · IF 4.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

胰腺腺癌(PAAD)是一种恶化迅速、预后较差的恶性肿瘤。研究人员正在探索PAAD中的自噬,以寻找新的生物标志物和治疗靶点。采用多因素Cox回归分析构建了与自噬相关基因(ARG)相关的总生存期(OS)模型。以癌症基因组图谱(TCGA)-PAAD队列作为训练组,作为模型构建的基础。该预测模型通过多个外部数据集进行了验证。为评估模型性能,进行了受试者工作特征曲线(ROC)分析。通过研究人类蛋白质图谱(HPA)和癌症细胞系百科全书(CCLE),验证ARGs表达对癌细胞的影响。通过使用CIBERSORT完成了高-risk和低-risk组之间免疫浸润水平的比较。通过基因本体生物学过程(GO-BP)和京都基因与基因组百科全书(KEGG)分析,进一步分析了低/高-risk组之间的差异表达基因(DEGs),用于在Connectivity Map(CMap)中识别潜在的小分子化合物,随后用PANC-1细胞进行半数抑制浓度(IC50)检测。风险评分最终计算如下:BAK1 × 0.34 + ITGA3 × 0.38 + BAG3 × 0.35 + APOL1 × 0.26-RAB24 × 0.67519。

ITGA3和RAB24在多因素Cox回归中均作为独立预后因素出现。每个PAAD队列中,高-risk组的OS均显著短于低-risk组。高-risk组表现出多种免疫细胞类型的浸润,包括初始B细胞(p = 0.003)、浆细胞(p = 0.044)和CD8 T细胞(接近显著,p = 0.080)。高风险组中NK细胞(p = 0.025)、静息巨噬细胞(p = 0.020)和肥大细胞(p = 0.007)的浸润水平高于低风险组。特征性ARGs的体外和体内表达在CCLE和HPA数据库中一致。富集程度最高的前3个基因本体生物学过程(GO-BPs)为信号释放、跨突触信号传导调控和化学突触传递调节,富集程度最高的前3个京都基因与基因组百科全书(KEGG)通路为MAPK、cAMP和细胞黏附分子。还鉴定出4种靶向ARGs的潜在小分子化合物(piperacetazine、vinburnine、withaferin A和hecogenin)。综合上述结果,我们的研究表明,ARG特征可能作为有用的预后指标,并揭示PAAD患者的潜在治疗靶点。

展开英文摘要原文

Adenocarcinoma of the pancreas (PAAD) is a cancerous growth that deteriorates rapidly and has a poor prognosis. Researchers are investigating autophagy in PAAD to identify a new biomarker and treatment target. An autophagy-related gene (ARG) model for overall survival (OS) was constructed using multivariate Cox regression analyses. A cohort of the Cancer Genome Atlas (TCGA)-PAAD was used as the training group as a basis for model construction. This prediction model was validated with several external datasets. To evaluate model performance, the analysis with receiver operating characteristic curves (ROC) was performed. The Human Protein Atlas (HPA) and Cancer Cell Line Encyclopedia (CCLE) were investigated to validate the effects of ARGs expression on cancer cells. Comparing the levels of immune infiltration between high-risk and low-risk groups was finished through the use of CIBERSORT. The differentially expressed genes (DEGs) between the low-/high-risk groups were analyzed further via Gene Ontology biological process (GO-BP) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, which were used to identify potential small-molecule compounds in Connectivity Map (CMap), followed by half-maximal inhibitory concentration (IC50) examination with PANC-1 cells. The risk score was finally calculated as follows: BAK1 × 0.

34 + ITGA3 × 0. 38 + BAG3 × 0. 35 + APOL1 × 0. 26-RAB24 × 0. 67519. ITGA3 and RAB24 both emerged as independent prognostic factors in multivariate Cox regression. Each PAAD cohort had a significantly shorter OS in the high-risk group than in the low-risk group. The high-risk group exhibited infiltration of several immune cell types, including naive B cells (p = 0. 003), plasma cells (p = 0. 044), and CD8 T cells (nearly significant, p = 0. 080). Higher infiltration levels of NK cells (p = 0. 025), resting macrophages (p = 0. 020), and mast cells (p = 0. 007) were found in the high-risk group than the low-risk group.

The in vitro and in vivo expression of signature ARGs was consistent in the CCLE and HPA databases. The top 3 enriched Gene Ontology biological processes (GO-BPs) were signal release, regulation of transsynaptic signaling, and modulation of chemical synaptic transmission, and the top 3 enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were MAPK, cAMP, and cell adhesion molecules.

Four potential small-molecule compounds (piperacetazine, vinburnine, withaferin A and hecogenin) that target ARGs were also identified. Taking the results together, our research shows that the ARG signature may serve as a useful prognostic indicator and reveal potential therapeutic targets in patients with PAAD.

论文信息

作者
Deng J、Zhang Q、Lv L、Ma P、Zhang Y、Zhao N、Zhang Y
第一作者单位
Institute of Health Service and Transfusion Medicine, Beijing, 100850, People's Republic of China.China
通讯作者单位
Institute of Health Service and Transfusion Medicine, Beijing, 100850, People's Republic of China. swgczhyy@126.com.China
文献类型
非美国政府资助研究
期刊
Scientific reports2022 Apr 29
原文标识
PubMed 35488119 · DOI 10.1038/s41598-022-11050-w